IRNOCAM 40MG INJECTION 2ML

Out of stock
SKU
IRN0002
₹777.50 Inclusive of all taxes
Manufacturer : DRL-DR REDDYS LABORATORIES
Composition : IRINOTECAN-100MG/5ML
Dose Form : INJECTION
Description : IRNOCAM 40 MG/2 ML INJ
Route Of Administration : PARENTERAL
Pack : 1

Discontinued for Online Sales

Kindly visit our store near you if you wish to purchase this medicine:

https://www.apollopharmacy.in//store-locator/

Drug Ingredient Information

IRINOTECAN-100MG/5ML

IRINOTECAN

Information for patients
Drug Information Irinotecan is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Irinotecan is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.
Drug Alert
Alert
Before Consuming the Medicine
Avoid Drug contraindicated in :Inflammatory bowel disease, bowel obstruction, severe hepatic impairment. Pregnancy and lactation.
Drug Special Care special precautions: Previous pelvic/abdominal irradiation; elderly; Raised plasma-bilirubin concentration; severe myelosuppression. Avoid extravasation.
Drug Drug Interactions Diuretics increase risks of dehydration secondary to vomiting/diarrhoea; prophylactic dexamethasone as an antiemetic may enhance lymphocytopenia; prochlorperazine may increase incidence of akathisia; antineoplastic agents (myelosuppression and diarrhoea). St John's wort, ketoconazole may reduce irinotecan exposure.
Drug Pregnancy Interaction Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Drug Breast feeding Interaction In lactating rats, 14C-irinotecan was detected in milk. It is not known whether irinotecan is excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, breast-feeding must be discontinued for the duration of irinotecan therapy
Drug Machinery Interaction Patients should be warned about the potential for dizziness or visual disturbances which may occur within 24 hours following the administration of irinotecan, and advised not to drive or operate machinery if these symptoms occur.
Drug More Information
How to take the Medicine
Consumption Info
Drug quanitty Intravenous Refractory colorectal malignancies Adult: 125 mg/m2 infused IV over 90 min once wkly for 4 wk followed by a 2 wk rest period. Or, 350 mg/m2 infused IV over 90 min repeated once every 3 wk. Hepatic impairment: Dose reduction may be necessary. Reconstitution: Dilute in 5% dextrose injection (preferred) or 0.9% sodium chloride injection to a final concentration of 0.12-2.8 mg/ml. Intravenous Metastatic colorectal cancer Adult: As 1st line treatment: 125 mg/m2 infused IV over 90 min on days 1,8,15 and 22 of a 6 wk cycle. Alternatively 180 mg/m2 infused IV over 90 min on days 1,15 and 29 of a 6 wk cycle. Hepatic impairment: Dose reduction may be necessary. Reconstitution: Dilute in 5% dextrose injection (preferred) or 0.9% sodium chloride injection to a final concentration of 0.12-2.8 mg/ml.
Drug Dose
Excess Drug Consumption
Forgot Drug Consumption
Stop Drug Consumption
Possible Side Effects
General Information Neutropenia, anaemia, thrombocytopenia; acute diarrhoea, sweating, hypersalivation, abdominal cramps, lachrymation, miosis, weakness; nausea, vomiting, alopecia and skin reactions; cardiovascular toxicity. Potentially Fatal: Fatal sepsis due to myelosuppression; severe, chronic diarrhoea.
Common Drug Side Effects
Rare Drug Side Effects
Very Rare Drug Side Effects
Drug Side Effects Symptoms
How to Store the Medicine
How to Store the Medicine Store in the original package in order to protect from light. Do not freeze.

Substitute Drugs

Write Your Own Review
You're reviewing:IRNOCAM 40MG INJECTION 2ML
Your Rating